Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. March 18, 2019. Cisco Vicenty.

Executive Summary

US FDA is approving 30-day change notices at a breakneck pace for device-makers enrolled in an agency program that measures manufacturing maturity and quality. See what FDA's Cisco Vicenty said about it here.

"The average time now is … probably 2.8 days to approval for change notices [for firms enrolled in FDA's Case for Quality Voluntary Improvement Program]. One of the more interesting things we're seeing … is that some notices are being approved even more quickly than that." –Cisco Vicenty, program manager, Office of Compliance, US FDA Center for Devices and Radiological Health

Click here for a free trial of Medtech Insight

 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel